论文部分内容阅读
目的:探讨坤泰胶囊联合Gn RH-a治疗40例中重度子宫内膜异位症患者的临床疗效以及对预后进行分析。方法:选取2013年2月—2015年8月在医院经手术证实的中重度子宫内膜异位症患者40例,采用随机数表法分为观察组和对照组各20例,对照组给予Gn RH-a治疗,观察组给予坤泰胶囊联合Gn RH-a治疗,比较两组患者治疗后性激素水平变化情况、治疗前后Kuppeman评分以及VAS评分变化情况、主要绝经期症状发生率情况以及治疗后临床疗效情况。结果:治疗前两组患者的性激素水平比较差异无统计学意义(P>0.05),治疗后,两组患者的E2、LH以及FSH都有所下降,但观察组(54.12±5.45)pmol/L、(2.78±0.14)U/L、(3.12±0.21)U/L低于对照组(70.56±9.78)pmol/L、(3.78±0.54)U/L、(4.98±0.10)U/L,两组比较差异显著(P<0.05);治疗后,两组患者的Kuppeman评分都有所上升,观察组(12.45±3.12)分高于对照组(8.45±2.98)分,两组患者的VAS评分都有所降低,观察组(3.12±0.12)分低于对照组(4.98±0.23)分,两组比较差异显著(P<0.05);观察组患者潮热、情绪波动、乏力、阴道干涩、骨痛以及睡眠障碍发生率低于对照组,两组患者治疗差异显著(P<0.05);观察组患者治疗后的总缓解率为95.00%高于对照组患者70.00%,两组患者比较差异显著(P<0.05)。结论:坤泰胶囊联合Gn RH-a治疗中重度子宫内膜异位症,可有效减轻Gn RH-a引起的部分雌激素低落症状,临床效果显著。
Objective: To investigate the clinical efficacy of Kuntai capsule combined with Gn RH-a in the treatment of 40 patients with moderate-severe endometriosis and to analyze the prognosis. Methods: Forty patients with moderate-severe endometriosis confirmed by surgery in our hospital from February 2013 to August 2015 were randomly divided into observation group (20 cases) and control group (20 cases). The control group was given Gn RH-a treatment. The observation group was treated with Gutai Capsule combined with Gn RH-a. The changes of sex hormone level, Kuppeman score and VAS score before and after treatment, the incidence of the main menopausal symptoms and the post-treatment clinical outcome were compared between the two groups Efficacy. Results: There was no significant difference in sex hormones between the two groups before treatment (P> 0.05). After treatment, the levels of E2, LH and FSH decreased in both groups. However, the observation group (54.12 ± 5.45) pmol / L , (2.78 ± 0.14) U / L and (3.12 ± 0.21) U / L were lower than those in the control group (70.56 ± 9.78 pmol / L, 3.78 ± 0.54 U / L and 4.98 ± 0.10 U / (P <0.05). After treatment, the Kuppeman scores increased in both groups (12.45 ± 3.12) compared with the control group (8.45 ± 2.98). The VAS scores of both groups were significantly higher than those of the control group (3.12 ± 0.12) points lower than the control group (4.98 ± 0.23) points, the difference between the two groups was significant (P <0.05); the observation group, hot flashes, mood swings, fatigue, vaginal dryness, pain (P <0.05). The total remission rate after treatment in the observation group was 95.00%, which was significantly higher than that in the control group (70.00%), and there was significant difference between the two groups (P <0.05). Conclusion: Gutai capsule combined with Gn RH-a in the treatment of moderate-severe endometriosis can effectively alleviate some estrogen-lowering symptoms caused by Gn RH-a. The clinical effect is significant.